Therapy of Histiocytosis X With Vincristine, Vinblastine, and Cyclophosphamide
- 1 February 1972
- journal article
- research article
- Published by American Medical Association (AMA) in American Journal of Diseases of Children
- Vol. 123 (2) , 105-110
- https://doi.org/10.1001/archpedi.1972.02110080083004
Abstract
We report the use of vincristine sulfate, vinblastine sulfate, and cyclophosphamide in the treatment of children with histiocytosis X. No children with solitary eosinophilic granulomas are included in this study. The complete remission rates for the three drugs were 50%, 20%, and 36%, respectively; and the complete remission plus partial remission rates are 50%, 55%, and 63%, respectively. Because of the small numbers of patients involved, and the design of the study, we could reach no conclusions regarding the relative efficacy of the drugs. We discuss factors influencing the response and present tabulated data regarding age, degree of involvement, duration of therapy, and result of therapy for each patient.Keywords
This publication has 4 references indexed in Scilit:
- Successful Treatment of an Infant with Letterer—Siwe Disease with Vinblastine SulfateClinical Pediatrics, 1970
- THERAPY OF HISTIOCYTOSIS XBritish Journal of Dermatology, 1970
- Treatment of reticuloendotheliosis with vinblastine sulfate: Preliminary reportThe Journal of Pediatrics, 1963
- Prognosis in reticuloendotheliosis in childrenThe Journal of Pediatrics, 1962